Zika Virus: Long-term Effects and Vaccine Development Efforts


Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 02 | 01 | Page : –
    By

    Vishwa Mehta,

  1. Assistant Professor, Department of Pharmacology, L. M. College of Pharmacy, Opp. Gujarat University, Navrangpura, Ahmedabad, Gujarat 380009, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_177604’);});Edit Abstract & Keyword

Zika virus (ZIKV) is a mosquito-borne flavivirus that gained international concern following the 2015-2016 outbreak in the Americas. Although most ZIKV infections are asymptomatic or mild, the virus presents significant public health risks due to its ability to cause severe neurological complications, especially in pregnant women and their offspring.Congenital Zika Syndrome (CZS) encompasses a range of fetal abnormalities, including microcephaly, vision impairment, hearing loss, and developmental delays. Infants exposed to ZIKV in utero may experience long- term neurodevelopmental challenges, including cognitive impairments, motor dysfunction, and epilepsy. In addition to its devastating impact on newborns, ZIKV has been linked to neurological disorders in adults, such as Guillain-Barré Syndrome (GBS), which can cause temporary or permanent paralysis. Emerging research suggests that ZIKV may also contribute to other neurological and autoimmune conditions, though further studies are needed to understand its full spectrum of effects.Efforts to combat ZIKV include vaccine development, vector control strategies, and enhanced surveillance programs. While promising vaccine candidates have been developed, challenges such as cross-reactivity with other flaviviruses like dengue and ethical considerations in clinical trials hinder rapid deployment. Strengthening global surveillance systems and implementing integrated public health initiatives are crucial for early outbreak detection and response.Despite significant progress in vaccine research, challenges such as cross- reactivity with other flaviviruses and ethical concerns in clinical trials persist. Continuous surveillance and integrated public health initiatives remain essential for controlling future ZIKV outbreaks and minimizing their long-term effects.

Keywords: Mosquito-borne, Neurological, Microcephaly, Neurodevelopmental, Autoimmune.

How to cite this article:
Vishwa Mehta. Zika Virus: Long-term Effects and Vaccine Development Efforts. International Journal of Virus Studies. 2025; 02(01):-.
How to cite this URL:
Vishwa Mehta. Zika Virus: Long-term Effects and Vaccine Development Efforts. International Journal of Virus Studies. 2025; 02(01):-. Available from: https://journals.stmjournals.com/ijvs/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_177604’);});Edit

References

  1. Dick GW, Kitchen SF, Haddow AJ. Zika virus (I). Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509-520.
  2. Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev. 2016;29(3):487-524.
  3. Ortenzio E, Matheron S, de Lamballerie X, Hubert B, Piorkowski G, Maquart M, et al. Evidence of sexual transmission of Zika virus. N Engl J Med. 2016;374(22):2195-2198.
  4. Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951-958.
  5. World Health Organization. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. 2016 Feb 1. Available from: https://www.who.int/news/item/01-02-2016.
  6. Petersen LR, Jamieson DJ, Honein MA. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med. 2016;374(20):1981-1987.
  7. Brasil P, Pereira JP, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321-2334.
  8. Ventura CV, Maia M, Ventura BV, Linden VV, Araújo EB, Ramos RC, et al. Ophthalmological findings in infants with microcephaly and presumable intrauterine Zika virus infection. JAMA Ophthalmol. 2016;134(5):529-535.
  9. Pessoa A, van der Linden V, Yeargin-Allsopp M, Carvalho MDCG, Ribeiro EM, Van Naarden Braun K, et al. Motor abnormalities and epilepsy in infants and children with evidence of congenital Zika virus infection. Pediatrics. 2018;141(Suppl 2):S167-S179.
  10. Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection—U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(31):858-867.
  11. Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016;375(16):1513-1523.
  12. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539.
  13. Carteaux G, Maquart M, Bedet A, Contou D, Brugières P, Fourati S, et al. Zika virus associated with meningoencephalitis. N Engl J Med. 2016;374(16):1595-1596.
  14. Bell TM, Field EJ, Narang HK. Zika virus infection of the central nervous system of mice. Arch Gesamte Virusforsch. 1971;35(2):183-193.
  15. Mead PS, Duggal NK, Hook SA, Delorey MJ, Fischer M, Olzenak McGuire D, et al. Zika virus shedding in semen of symptomatic infected men. N Engl J Med. 2018;378(15):1377-1385.
  16. Barzon L, Pacenti M, Franchin E, Pagni S, Martello T, Cattelan AM, et al. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro Surveill. 2016;21(32):30316.
  17. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852-7857.
  18. Vermillion MS, Lei J, Shabi Y, Baxter VK, Crilly NP, McLane M, et al. Intrauterine Zika virus infection of pregnant immunocompetent mice models transplacental transmission and fetal pathogenesis. Cell Host Microbe. 2017;21(5):617-628.e8.
  19. Shah SK, Gibbs SE, Aliu O, Lyerly AD, Zika Ethics Working Group. Ethical considerations for Zika virus vaccine development. Vaccine. 2017;35(6):681-686.
  20. Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, et al. Preliminary aggregate safety and immunogenicity of a Zika vaccine in three phase 1 clinical trials. Lancet. 2018;391(10120):563-571.
  21. Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, et al. Vaccine-mediated protection against Zika virus-induced congenital disease. Cell. 2017;170(2):273-283.e12.
  22. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med. 2017;23(6):763-767.
  23. Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine. N Engl J Med. 2017;376(20):1932-1942.
  24. World Health Organization. Zika virus surveillance guidelines. Geneva: WHO; 2016. Available from: https://www.who.int/emergencies/zika-virus/surveillance.
  25. Likos A, Griffin I, Bingham AM, Stanek D, Fischer M, White S, et al. Local mosquito-borne transmission of Zika virus—Miami-Dade and Broward Counties, Florida, June–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(38):1032-1038.
  26. Sanz Cortes M, Rivera AM, Al-Khan A, Guevara-Campos J, Howell J, Harirah H, et al. Maternal and fetal Zika virus infection: a comprehensive review of management. Arch Gynecol Obstet. 2017;296(1):15-22.
  27. Neill SL, Ryan PA, Turley AP, Wilson G, Retzki K, Iturbe-Ormaetxe I, et al. Scaled deployment of Wolbachia to protect the community from dengue and other Aedes-transmitted arboviruses. Gates Open Res. 2018;2:36.
Ahead of Print Subscription Review Article
Volume 02
01
Received 27/02/2025
Accepted 07/03/2025
Published 11/03/2025
Publication Time 12 Days
131

async function fetchCitationCount(doi) {
let apiUrl = `https://api.crossref.org/works/${doi}`;
try {
let response = await fetch(apiUrl);
let data = await response.json();
let citationCount = data.message[“is-referenced-by-count”];
document.getElementById(“citation-count”).innerText = `Citations: ${citationCount}`;
} catch (error) {
console.error(“Error fetching citation count:”, error);
document.getElementById(“citation-count”).innerText = “Citations: Data unavailable”;
}
}
fetchCitationCount(“10.37591/IJVS.v02i01.0”);

Loading citations…